A Phase 1 interventional study of PEG-Intron in Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-07.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing peginterferon alfa-2b in Melanoma — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Melanoma.
Among the 14 studies testing peginterferon alfa-2b in Melanoma, this one is the 9th largest by enrollment, is the only one that started in 2007, is one of 5 in phase 1, and was the 4th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →None of the 14 studies testing peginterferon alfa-2b in Melanoma is open now. The open studies under Melanoma, anywhere →
peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 7 · Phase 3 3
First in 1998; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 36 across the 14 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
42 studies in Melanoma by Merck & Co., Inc: 1 open now, 6 under way, 3 of them phase 3. Of 34 finished, 25 (74%) have results posted.
Among the 42 studies in Melanoma by Merck & Co., Inc, this one is the 33rd largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2007, is one of 13 in phase 1, and was the 2nd registered.
Merck & Co., Inc’s Melanoma studies by the year they started, since 1996.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing peginterferon alfa-2b in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 42 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to establish the pharmacokinetics of PEG-Intron, administered at a dose of 6 μg/kg/week for 8 weeks (induction treatment), followed by a dose of 3 μg/kg/week for up to 252 weeks (maintenance treatment), in patients with high risk melanoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Clinical diagnosis of substance abuse of one or more of the following drugs within the following timeframes (excluding time spent in detoxification, hospitalization or incarceration):
Marijuana:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6 ug/kg/week, SC (first 8 weeks) 3 ug/kg/week, SC (252 weeks \[weeks 9-260\], maintenance)
Drug: PEG-Intron
Also known as: SCH 054031, peginterferon alfa-2b
Area Under the Curve (AUC) of PEG-Intron at 12 Weeks
AUC was defined as the actual body exposure to drug after administration of a dose of the drug.
Time frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Maximum Serum Concentration (Cmax) of PEG-Intron at 12 Weeks
Cmax was defined as observed maximum plasma concentration.
Time frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Average Concentration Within the Dosing Interval (Cavg) of PEG-Intron at 12 Weeks
Cavg was defined as average plasma concentration.
Time frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Minimum Serum Concentration (Cmin) of PEG-Intron at 12 Weeks
Cmin was defined as observed minimum plasma concentration.
Time frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Observed Time to Achieve Cmax (Tmax) of PEG-Intron at 12 Weeks
Tmax was defined as time of maximum plasma concentration.
Time frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Apparent Clearance(CL/F) of PEG-Intron at 12 Weeks
CL/F was defined apparent clearance - the volume of plasma in the vascular compartment cleared of drug per unit of time and per kilogram of body weight by the processes of metabolism and excretion.
Time frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Number of Participants Who Experienced an Adverse Event (AE)
An adverse event (AE) was defined as any untoward medical occurrence or unfavorable and unintended sign in a subject administered a pharmaceutical product, biologic (at any dose), or medical device, whether or not considered related to the use of that product.
Time frame: Entire study duration (up to 5 years)
| Milestone | PEG-Intron |
|---|---|
| Started | 32 |
| Completed | 27 |
| Not completed | 5 |
| Withdrew: Adverse event | 2 |
| Withdrew: Progression of disease | 1 |
| Withdrew: Non-compliance with protocol | 2 |
| Milestone | PEG-Intron |
|---|---|
| Started | 31 |
| Completed | 3 |
| Not completed | 28 |
| Withdrew: Adverse event | 10 |
| Withdrew: Progression of disease | 6 |
| Withdrew: Withdrawal by subject | 11 |
| Withdrew: Lost to follow-up | 1 |
AUC was defined as the actual body exposure to drug after administration of a dose of the drug.
| pg*hr/mL | PEG-Intron |
|---|---|
| Area Under the Curve (AUC) of PEG-Intron at 12 Weeks | 235000 ± 56400 |
Cmax was defined as observed maximum plasma concentration.
| pg/mL | PEG-Intron |
|---|---|
| Maximum Serum Concentration (Cmax) of PEG-Intron at 12 Weeks | 2620 ± 865 |
Cavg was defined as average plasma concentration.
| pg/mL | PEG-Intron |
|---|---|
| Average Concentration Within the Dosing Interval (Cavg) of PEG-Intron at 12 Weeks | 1400 ± 336 |
Cmin was defined as observed minimum plasma concentration.
| pg/mL | PEG-Intron |
|---|---|
| Minimum Serum Concentration (Cmin) of PEG-Intron at 12 Weeks | 626 ± 269 |
Tmax was defined as time of maximum plasma concentration.
| hours | PEG-Intron |
|---|---|
| Observed Time to Achieve Cmax (Tmax) of PEG-Intron at 12 Weeks | 24.00 (24.00 to 48.00) |
CL/F was defined apparent clearance - the volume of plasma in the vascular compartment cleared of drug per unit of time and per kilogram of body weight by the processes of metabolism and excretion.
| L/hr/kg | PEG-Intron |
|---|---|
| Apparent Clearance(CL/F) of PEG-Intron at 12 Weeks | 0.0129 ± 0.00284 |
An adverse event (AE) was defined as any untoward medical occurrence or unfavorable and unintended sign in a subject administered a pharmaceutical product, biologic (at any dose), or medical device, whether or not considered related to the use of that product.
| participants | PEG-Intron |
|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 32 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEG-Intron | — | 9/32 (28.1%) | 32/32 (100%) |
| Event | PEG-Intron |
|---|---|
| ATRIAL FIBRILLATIONCardiac disorders | 2/32 |
| CARDIAC ARRESTCardiac disorders | 1/32 |
| GLAUCOMAEye disorders | 1/32 |
| CHOLECYSTITISHepatobiliary disorders | 1/32 |
| DRUG HYPERSENSITIVITYImmune system disorders | 1/32 |
| APPENDICITIS PERFORATEDInfections and infestations | 1/32 |
| BRONCHITISInfections and infestations | 1/32 |
| SEPSISInfections and infestations | 1/32 |
| LOWER LIMB FRACTUREInjury, poisoning and procedural complications | 1/32 |
| WRIST FRACTUREInjury, poisoning and procedural complications | 1/32 |
| Event | PEG-Intron |
|---|---|
| FATIGUEGeneral disorders | 29/32 |
| PYREXIAGeneral disorders | 27/32 |
| DECREASED APPETITEMetabolism and nutrition disorders | 27/32 |
| CHILLSGeneral disorders | 26/32 |
| NAUSEAGastrointestinal disorders | 23/32 |
| HEADACHENervous system disorders | 23/32 |
| DIARRHOEAGastrointestinal disorders | 20/32 |
| MYALGIAMusculoskeletal and connective tissue disorders | 18/32 |
| INJECTION SITE REACTIONGeneral disorders | 13/32 |
| HYPERTRIGLYCERIDAEMIAMetabolism and nutrition disorders | 13/32 |
| Age, Continuous(years) | PEG-Intron |
|---|---|
| Mean | 49.1 ± 12.8 |
| Sex: Female, Male(Participants) | PEG-Intron |
|---|---|
| Female | 10 |
| Male | 22 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Feb 2007 to primary completion in May 2008, 15 months.
Results were first posted in Jul 2013, 5 years 2 months after primary completion.
Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 15 months is below that.
Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2b